Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Chemotherapy and AuBMT in Aggressive Non-Hodgkin's Lymphoma
NCT00003815Phase 3Unknown
- Sponsor
- Scotland and Newcastle Lymphoma Group
- Start
- Jun 1994
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan, carmustine, etoposide and cytarabine in non-Hodgkin lymphoma (NHL) (5 arms), sponsored by Scotland and Newcastle Lymphoma Group. Primary endpoints: Rate of Remission, Efficacy of Regimen and 1 more. Status: unknown.
02
Drugs
melphalancarmustineetoposidecytarabine
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003815.